1. |
王吉耀. 主编. 循证医学与临床实践. 第1版. 北京: 科学出版社; 2002. 55~81, 86~121.
|
2. |
朱晓松, 邵黎. 肺癌患者的免疫状态及肺癌的免疫治疗. 中国肺癌杂志, 2000; 3(2): 158~160.
|
3. |
张鸣明, 李静. 从患者角度看循证医学. 医学与哲学, 2005; 26(8): 55~56.
|
4. |
Ihde DC, Pass HI, Glastein E. Small cell lung cancer. In: De Vita VT Jr, Hellman S, Rosenberg SA(eds). Cancer Principles and Practice of Oncology, 5th ed. Philadelphia: Lippincott-Raven; 1997. 911–949.
|
5. |
Carney DN, Shepherd FA. Treatment of SCLC: Chemotherapy, in Hansen HH: Textbook of Lung cancer. London, Martin Donitz LTD; 2000. 261–272.
|
6. |
Feld R, Evans WK, DeBoer G, et al. Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol, 1984; 2(4): 294–304.
|
7. |
Laurie SA, Logan D, Markman BR, et al. Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer, 2004; 43(2): 223–240.
|
8. |
Mattson K, Niiranen A, Pyrhonen S, et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer, 1992; 28A(8-9): 1387–1391.
|
9. |
Lebeau B, Delasalamoniere P, Ozeanne G, et al. alpha Interferon (alpha-IFN) as maintenance therapy for small cell lung cancer(SCLC). J Clin Oncol, 1999; 17(suppl): 1832.
|
10. |
Ruotsalainen T, Halme M, Isokangas OP, et al. Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feasibility study. Anticancer Drugs, 2000; 11(2): 101–108.
|
11. |
Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol, 1994; 12(11): 2321–2326.
|
12. |
van Zandwijk N, Groen HJ, Postmus PE, et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer, 1997; 33(11): 1759–1766.
|
13. |
Mattson K, Niiranen A, Ruotsalainen T, et al. Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. J Interferon Cytokine Res, 1997; 17(2): 103–105.
|
14. |
Kelly K, Crowley JJ, Bunn PA Jr, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol, 1995; 13(12): 2924–2930.
|
15. |
Wang JY. Chief Editor. Evidence-Based Medicine and Clinical Practice. 1st edition. Beijing: Science Press; 2002. 55–81, 86–121.
|
16. |
Zhu XS, Shao L. Immune status of lung cancer patients and immunotherapy of lung cancer. Chinese J. Lung Cancer, 2000; 3(2): 158–160.
|
17. |
Tagliaferri P, Caraglia M, Budillon A. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother, 2005; 54(1): 1–10.
|
18. |
Matsumoto K, Okano J, Murawaki Y. Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol, 2005; 40(7): 722–732.
|
19. |
Zika E, Fauquier L, Vandel L, et al. Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression. Proc Natl Acad Sci USA, 2005; 102(45): 16321–16326.
|
20. |
Ruotsalainen TM, Mattson K. Interferon trials in small cell lung cancer at one institution: a comparison of results obtained before and after initiation of systematic treatment trials using IFN-alpha in combination with other modalities. J Interferon Cytokine Res, 2002; 22(2): 165–171.
|
21. |
Jones DH, Bleehen NM, Slater AJ, et al. Human lymphoblastoid interferon in the treatment of small cell lung cancer. Br J Cancer, 1983; 47(3): 361–366.
|
22. |
Villar J, Carroli G, Belizan JM. Predictive ability of meta-analyses of randomised controlled trials. Lancet, 1995, 345(8952): 772–776.
|
23. |
Zhang MM, Li J. Evidence-based medicine: from a point of view of patient. Medicine and Philosophy, 2005; 26(8): 55–56.
|